You are here

Humira

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

EP Vantage

hidradenitis suppurativa

Flag link:

AbbVie's Humira, 5 Pfizer drugs among those with price hikes that exceeded inflation rate

AbbVie's Humira, 5 Pfizer drugs among those with price hikes that exceeded inflation rate

Fierce Pharma

Flag link:

AbbVie braces for 'greater erosion' of Humira franchise in second half of this year

AbbVie braces for 'greater erosion' of Humira franchise in second half of this year

Endpoints

Flag link:

AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff

AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff

Fierce Pharma

Richard Gonzalez

Flag link:

Could This Humira Biosimilar Be a Winner for Amgen?

Could This Humira Biosimilar Be a Winner for Amgen?

Motley Fool

Flag link:

Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’

Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’

BioPharma Dive

Bristol Myers Squibb

Flag link:

Years after the first US biosim launches, doctors still have their concerns: survey

Years after the first US biosim launches, doctors still have their concerns: survey

Fierce Pharma

Flag link:

AbbVie talks next steps as first Humira competitor makes it to market

AbbVie talks next steps as first Humira competitor makes it to market

Endpoints

Flag link:

AbbVie opens up to bigger deals as competition heats up

AbbVie opens up to bigger deals as competition heats up

Endpoints

Flag link:

Amgen Adopts A Two-Price Strategy For The U.S.’s First Marketed Humira-Referenced Biosimilar, Amjevita

Amgen Adopts A Two-Price Strategy For The U.S.’s First Marketed Humira-Referenced Biosimilar, Amjevita

Forbes

Flag link:

Amgen launches Humira biosimilar, releases Q4 earnings report

Amgen launches Humira biosimilar, releases Q4 earnings report

Medical Marketing and Media

Flag link:

Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug

Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug

BioPharma Dive

Flag link:

The end of the Humira era

The end of the Humira era

EP Vantage

Flag link:

AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.

AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.

Motley Fool

Flag link:

Amgen prepped to take first slice of AbbVie’s US Humira pie

Amgen prepped to take first slice of AbbVie’s US Humira pie

BioProcess International

Flag link:

Looking past Humira, AbbVie boosts sales forecasts for successor drugs

Looking past Humira, AbbVie boosts sales forecasts for successor drugs

BioPharma Dive

Richard Gonzalez

Flag link:

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars

Drug Channels

Express Scripts

Flag link:

Optum to add biosimilars to formulary to tackle the massive cost of Humira

Optum to add biosimilars to formulary to tackle the massive cost of Humira

Fierce Healthcare

Flag link:

AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq

AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq

BioSpace

Flag link:

AbbVie preps for an onslaught of Humira biosimilars in 2023, with Skyrizi and Rinvoq to fill the gap for now

AbbVie preps for an onslaught of Humira biosimilars in 2023, with Skyrizi and Rinvoq to fill the gap for now

Endpoints

Flag link:

Pages